Trending News Today: PhRMA Concerned About President Trump's Plan to Lower Drug Prices

The Pharmaceutical Research and Manufacturers of America (PhRMA) expressed concerns about President Trump’s new plan to reduce drug prices, The Hill reported. According to the article, Lori Reilly, an executive vice president of PhRMA, said in a statement that several of the proposals would harm patient access to drugs. Particularly, Reilly raised concerns about the administration’s proposals to move drugs from Medicare Part B into Part D, the article reported.
Six more US states on Tuesday announced lawsuits against OxyContin maker Purdue Pharma LP, according to Reuters. The article reported that the states are accusing the company of fueling the opioid epidemic by deceptively marketing its prescription painkillers to generate billions of dollars in sales. US state attorney generals of Nevada, Texas, Florida, North Carolina, North Dakota, and Tennessee also said that Purdue Pharma violated state consumer protection laws by falsely denying or downplaying addiction risk while overstating the opioid’s benefits, according to the article.
According to a new study, physicians are often slow to switch patients to more intensive diabetes treatments when the patient’s disease isn’t well controlled, Reuters reported. In the study, researchers examined electronic health records for 7389 patients with poorly controlled diabetes between 2005 and 2016. The study’s findings indicated that only about one-third of patients with poorly controlled blood sugar on oral drugs were switched to higher doses, different drugs, or insulin within 6 months, according to the article.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Most Popular

Related Articles

The shift from fee-based, volume-driven care to value-based, patient-centered care and the growth of specialty pharmaceuticals are propelling us all into uncharted territory, no matter what role you play in health care.
Failure to recognize the interests of manufacturers to ensure proper use of 340B pricing may result in 340B hospitals missing the opportunity to secure and retain discounts on key orphan and specialty drugs or may render them unable to access the drugs at all.
This proposal, outlined by the Centers for Medicare & Medicaid Services (CMS) in late 2018, would undermine CMS’ stated goal of prioritizing value and improved patient outcomes over utilization and sickness.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.